Lead Product(s) : Pocenbrodib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation. In preclinical studies, FT-7501 demonstrated activity in both prostate cancer models that were sensitive.
Product Name : FT-7051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Pocenbrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Rigel Pharmaceuticals
Deal Size : $235.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Rigel Pharmaceuticals will develop, manufacture and commercialize FT-2102 (olutasidenib), an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia and ...
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : $2.0 million
February 08, 2022
Lead Product(s) : Olutasidenib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Rigel Pharmaceuticals
Deal Size : $235.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-2102 (Olutasidenib) in combination with Vidaza (Azacitidine) is found to be well-tolerated and, yielded durable complete remission in the first Phase 2 combination trial in patients with the mIDH1 form of acute myeloid leukemia.
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pocenbrodib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation.
Product Name : FT-7051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : Pocenbrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
Details : The Phase 1/2 study is a multicenter, open-label, multi-cohort evaluation of the safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of olutasidenib for patients with AML or myelodysplastic syndrome (MDS) with an IDH1 mutation.
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pocenbrodib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-7051 is a selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300) and a co-activator of androgen receptor. Phase 1 study includes late-line patients and patients with AR-v7 splice variants for whom there are no approved therapi...
Product Name : FT-7051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2021
Lead Product(s) : Pocenbrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT2102-HEM-101 clinical trial data demonstrate a 30% CR and 3% CRh rate with olutasidenib monotherapy in 123 relapsed or refractory IDH1m AML patients.
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Forma Therapeutics Announces Clinical Data to be Presented at ASCO20 Virtual Scientific Program
Details : Oral presentation to highlight clinical data for olutasidenib, an investigational agent, in IDH1 mutant gliomas, including confirmation of blood-brain barrier penetration and preliminary disease control for patients with recurrent, predominantly enhanced...
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2020
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT-6876
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings support potential efficacy of Forma’s biomarker-driven therapy to reduce cell proliferation and inhibit tumor growth.
Product Name : FT-6876
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : FT-6876
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FORMA Therapeutics Announces Publication of Olutasidenib’s Molecular Design and Potential Utility
Details : Potent CNS-penetrant, selective IDH1m inhibitor has potential utility in targeting hematologic malignancies, solid tumors and gliomas
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable